Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 17/20 | 1.00 |
| ▸ | NAMPT | P43490 | 1/20 | 0.62 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3651635 | 0.90 | KDR (1.00) | KDRNAMPTROCK1 | |
| SCHEMBL445668 | 0.84 | KDR (0.73) | KDRNAMPTLIMK1ROCK1 | |
| SCHEMBL6330184 | 0.84 | KDR (1.00) | KDRLIMK1 | |
| SCHEMBL20380021 | 0.83 | KDR (0.79) | KDRNAMPTROCK1 | |
| SCHEMBL6330218 | 0.83 | KDR (0.79) | KDRNAMPTLIMK1ROCK1 | |
| SCHEMBL6332623 | 0.83 | KDR (0.79) | KDRNAMPTLIMK1ROCK1 | |
| SCHEMBL5889206 | 0.80 | KDR (1.00) | KDR | |
| SCHEMBL6336620 | 0.80 | KDR (0.74) | KDRNAMPTROCK1 | |
| SCHEMBL6282391 | 0.80 | CNR1 (0.74) | KDRNAMPTROCK1 | |
| SCHEMBL3606835 | 0.79 | KDR (0.79) | KDRNAMPTLIMK1ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050228031-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T | 2005-10-13 | — | — | US | claimed |
| US-20050228031-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228031-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885NAMPT 1058/4885LIMK1 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.